Kymera Therapeutics KYMR Cash Flow Statement (2019-2026)

NASDAQ KYMR
$117.45 +0.17 (+0.14%)
As of: Sep 4, 2026 · 3:59 PM EDT
Reported Financials

Kymera Therapeutics Quarterly Cash Flow Statement

Periods 28 quarters
Latest Jun 2026

Kymera Therapeutics reported cash from operations of -$54.06M and free cash flow of -$51.90M for the quarter ended Jun 2026, up 9.7% year over year. This cash flow statement covers 28 quarters of results from Sep 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-28.71M-34.05M-36.97M-40.85M-44.92M-38.69M-45.38M-43.43M-57.55M-19.36M-57.90M-50.99M-72.18M-80.81M-74.50M-84.67M-92.62M-97.99M-84.22M-75.69M
Share-based CompensationStock Comp.
7.40M8.68M7.87M9.62M9.08M8.91M48.83M11.18M11.65M11.97M14.34M14.90M13.80M14.23M15.41M15.80M14.45M16.01M18.94M
Asset Writedowns and ImpairmentWritedown
4.92M3.85M0.04M
Cash from OperationsCash from Ops.
-37.26M-38.35M-40.30M-38.98M-34.27M-39.54M-43.97M-35.26M-31.65M8.04M-39.59M-42.94M-50.19M-61.78M-79.15M-59.88M-27.11M-66.75M-88.84M-54.06M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
1.66M1.64M1.18M0.68M-0.06M-0.91M-1.33M-1.42M-1.22M-1.27M-3.07M-4.02M-3.62M-3.27M-2.52M-2.12M-2.19M-2.04M-2.73M-2.33M
Depreciation & Amortization (CF)Dep. & Amort.
0.67M0.69M0.69M0.70M0.77M0.82M0.88M0.90M0.90M0.89M1.46M1.94M1.99M1.99M2.05M2.08M2.15M2.03M2.02M2.03M
Change in Working Capital
Change in Account PayablesChange Payables
-2.92M-1.03M-1.44M-0.41M4.17M-2.07M2.22M-2.73M1.02M1.53M0.07M0.03M0.09M-0.51M3.92M-4.13M-0.27M-1.49M8.82M-3.94M
Change in Accured ExpensesChange Accured Exp.
4.71M3.80M-2.28M0.56M3.40M2.84M-10.04M3.79M2.64M6.79M-15.39M7.80M2.75M9.02M-11.69M4.75M0.66M13.66M-7.21M13.49M
Other Working Capital ChangesOther WC Changes
-18.76M-15.14M-8.36M-9.14M-6.67M-13.60M-6.14M-12.39M-0.95M10.88M-8.26M-23.95M-2.42M-6.45M-2.10M28.52M-2.76M-2.87M-34.37M
Investing Activities
Capital ExpendituresCapex
0.31M0.90M0.48M0.73M1.25M0.37M4.01M10.77M8.08M11.62M7.40M4.69M-0.19M0.94M0.47M2.26M-1.38M5.82M0.43M-2.16M
Change in Acquisitions & DivestmentsChange Acquisitions
109.29M96.88M106.46M147.25M117.67M97.94M90.43M99.25M97.76M76.08M99.50M124.49M138.07M147.93M132.74M118.97M132.44M103.87M133.86M135.17M
Cash from Investing ActivitiesCash from Investing
-136.86M-68.02M25.86M81.80M-37.48M-49.67M24.58M35.84M60.51M18.95M-330.61M15.64M-157.68M68.57M48.62M60.02M-235.30M-394.40M-142.84M20.05M
Financing Activities
Other financing activitiesOther financing
3.26M1.76M0.45M0.38M0.96M1.36M1.49M0.68M0.13M0.56M48.74M0.54M7.70M4.55M48.83M19.19M13.38M
Cash from Financing ActivitiesCash from Financing
246.04M2.05M0.18M0.36M150.50M1.95M1.16M1.30M-0.21M1.93M353.76M1.41M250.92M2.77M0.26M245.73M39.51M705.22M18.77M14.42M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
2.39M1.20M1.76M1.93M2.60M2.19M2.51M1.64M2.40M1.10M
Net Equity Issued and RepurchasedNet Equity Issued
Additional items
Change in Cash
71.92M-104.32M-14.25M43.18M78.75M-87.25M-18.23M1.89M28.66M28.93M-16.44M-25.88M43.05M9.55M-30.28M245.86M-222.90M244.07M-212.91M-19.60M
Free Cash FlowFCF
-37.57M-39.25M-40.78M-39.72M-35.52M-39.91M-47.98M-46.02M-39.73M-3.58M-46.99M-47.62M-50.00M-62.72M-79.62M-62.14M-25.73M-72.57M-89.27M-51.90M
Net Cash FlowNCF
71.92M-104.32M-14.25M43.18M78.75M-87.25M-18.23M1.89M28.66M28.93M-16.44M-25.88M43.05M9.55M-30.28M245.86M-222.90M244.07M-212.91M-19.60M